NEW · Biotechnology
ABBV
AbbVie Inc · $464.43B
262.82
+1.11%
Price
21 sessions shownTechnicals
from daily closesRSI · 14 day
53.1
Avg true range · 14d
1.80%
Volatility · 20d annualised
17.5%
Trend · 20d vs 50d
—
vs 20-day average
0.66%
vs 50-day average
—
vs 200-day average
—
200-day average
—
Internals
where it sits, and how hard it is being traded52-week low
190.75
52-week high
269.39
Volume vs its 20-day avg
—
Beta vs the market
0.20
Sitting 92% of the way up its 52-week range (190.75 → 269.39)
Swings
prices it actually turned at — highest or lowest of the surrounding 11 sessionsTurned down · Sep 23
269.39
Fundamentals
P/E
73.60
Fwd P/E
—
P/S
7.21
P/B
94.44
EV/EBITDA
29.96
ROE
95.6%
ROA
4.7%
Gross margin
72.8%
Net margin
—
Debt / equity
20.19
Rev growth
10.4%
EPS growth
-29.0%
Earnings
Next report
Oct 30, 2026
EPS expected
3.92
Beat in last 4
3 of 4
2026-06-30reported 3.65 vs 3.68 expected-0.7%
2026-03-31reported 2.65 vs 2.65 expected+0.2%
2025-12-31reported 2.71 vs 2.71 expected+0.2%
2025-09-30reported 1.86 vs 1.81 expected+2.7%
Analyst coverage
39 analysts · as of 2026-09-01Strong buy
10
Buy
22
Hold
7
Sell
0
Strong sell
0
News
stories naming this company, last 21 daysEvery figure here is measured from live market data as of Oct 4, 05:43 PM. Nothing is estimated or filled in — where a figure shows — the source had no value for it, and a section you don’t see had no data at all. This describes what the market has already done. It is not a forecast, and not financial advice.